ALZN Alzamend Neuro, Inc. Stock Quote

ALZN [NASD]

Index	-	P/E	-	EPS (ttm)	-0.11	Insider Own	3.70%	Shs Outstand	94.17M	Perf Week	-7.49%
Market Cap	77.92M	Forward P/E	-	EPS next Y	-0.20	Insider Trans	-	Shs Float	46.33M	Perf Month	-5.87%
Income	-9.70M	PEG	-	EPS next Q	-0.03	Inst Own	3.60%	Short Float	3.66%	Perf Quarter	-28.83%
Sales	-	P/S	-	EPS this Y	-14.40%	Inst Trans	284.05%	Short Ratio	2.19	Perf Half Y	-55.34%
Book/sh	0.13	P/B	6.73	EPS next Y	-58.30%	ROA	-83.60%	Target Price	11.25	Perf Year	-88.60%
Cash/sh	0.13	P/C	6.60	EPS next 5Y	-	ROE	-92.10%	52W Range	0.80 - 9.25	Perf YTD	-53.93%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-90.54%	Beta	-
Dividend %	-	Quick Ratio	26.60	Sales past 5Y	-	Gross Margin	-	52W Low	9.36%	ATR	0.06
Employees	2	Current Ratio	26.60	Sales Q/Q	-	Oper. Margin	-	RSI (14)	44.52	Volatility	5.41% 5.92%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-107.40%	Profit Margin	-	Rel Volume	0.15	Prev Close	0.86
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	772.79K	Price	0.88
Recom	2.00	SMA20	-3.12%	SMA50	-6.06%	SMA200	-45.75%	Volume	115,408	Change	1.27%

Oct-01-21

Initiated

Ascendiant Capital Markets

Buy

Jun-20-22 09:22AM	10 Best Biotech Penny Stocks To Buy Now Insider Monkey
Jun-03-22 08:00AM	Alzamend Neuro to Present at the 12th Annual LD Micro Invitational Business Wire
May-17-22 08:00AM	Alzamend Neuro Announces Pre-IND Submission for AL001 as a Treatment of Bipolar Disorder, Major Depressive Disorder and Post-Traumatic Stress Disorder Business Wire +7.25%
May-06-22 09:02AM	10 Biotech Penny Stocks Redditors Love Insider Monkey -6.74%
May-05-22 08:00AM	Alzamend Neuro Announces Initiation of Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimers Business Wire
May-04-22 06:25AM	What Kind Of Investors Own Most Of Alzamend Neuro, Inc. (NASDAQ:ALZN)? Simply Wall St.
Apr-28-22 06:30AM	BitNile Holdings Announces Additional Investment in Alzamend From Completion of Phase 1 First-in-Human Clinical Trial for AL001 Treatment of Dementia Related to Alzheimers Business Wire
06:30AM	Alzamend Neuro Announces $4 Million Additional Investment from Digital Power Lending Upon Completion of Phase 1 First-in-Human Clinical Trial for AL001 Treatment of Dementia Related to Alzheimers Business Wire
Apr-11-22 08:00AM	Alzamend Neuro Contracts with Altasciences and iResearch Atlanta to Manage and Conduct Its Phase IIA Study in Patients with Alzheimers Business Wire -6.25%
Apr-06-22 10:15AM	10 Biotech Penny Stocks with Growth Catalysts Insider Monkey
Apr-04-22 08:00AM	Alzamend Neuro Appoints Dr. Terri Hunter to Its Scientific Advisory Board Business Wire
Mar-28-22 08:00AM	Alzamend Neuro Announces Full Data Set From Phase 1 First-in-Human Clinical Trial for AL001 Treatment of Dementia Related to Alzheimers Business Wire
Mar-18-22 06:31AM	We're Hopeful That Alzamend Neuro (NASDAQ:ALZN) Will Use Its Cash Wisely Simply Wall St. +9.71%
Jan-13-22 04:00AM	ALZN: Coordinated Offensive on Alzheimers Disease Zacks Small Cap Research
Dec-17-21 09:54AM	Alzamend Neuro Shares Are Trading Higher After Encourage Early-Stage Data From Alzheimer's Candidate Benzinga
09:00AM	Alzamend Neuro Announces Positive Topline Data from Phase 1 First-in-Human Clinical Trial for AL001 Treatment of Dementia Related to Alzheimers Business Wire
Dec-14-21 06:35PM	Why Alzamend Neuro Stock Soared Today Motley Fool +28.33%
11:18AM	MIND Stock: The U.S. Navy Deal That Has Mind Technology Shares Surging Today InvestorPlace
09:29AM	ALZN Stock Alert: What Is Going on With Alzamend Neuro Today? InvestorPlace
Nov-30-21 08:30AM	Alzamend Neuro Announces Date for Delivery of Topline Data for Phase 1 First-in-Human Clinical Trial for AL001 for Dementia Related to Alzheimers Business Wire
Nov-11-21 07:17AM	28 Stocks Moving in Thursday's Pre-Market Session Benzinga +11.63%
Oct-01-21 09:24AM	Company News for Oct 1, 2021 Zacks -6.49%
04:44AM	51 Biggest Movers From Yesterday Benzinga
Sep-30-21 01:45PM	See Why Alzamend Neuro Stock Is Rallying On Thursday Benzinga +35.09%
12:09PM	36 Stocks Moving In Thursday's Mid-Day Session Benzinga
11:54AM	Why Alzamend Neuro Shares Are Surging Higher Today Benzinga
10:11AM	Alzamend Neuro Receives Positive Pre-IND Response from FDA for AL002, a Cell-Based Therapeutic Vaccine That Seeks to Restore the Ability of Patients Immunological System to Combat Alzheimers Disease Business Wire
Sep-16-21 06:09AM	ALZN: An Elemental Approach to Alzheimers Disease Zacks Small Cap Research
Sep-15-21 06:29AM	Could The Alzamend Neuro, Inc. (NASDAQ:ALZN) Ownership Structure Tell Us Something Useful? Simply Wall St.
Sep-13-21 06:30AM	Alzamend Neuro Announces Initiation of Phase I First-in-Human Clinical Trial for AL001 for Dementia Related to Alzheimers Disease Business Wire -5.76%
Aug-17-21 10:59AM	Alzamend Recruits Altasciences To Conduct Early-Stage Trial Of Its Alzheimer's Candidate Benzinga -5.71%
08:00AM	Alzamend Neuro Announces It Has Contracted With Altasciences to Conduct a Phase I Relative Bioavailability Study for AL001 for Dementia Related to Alzheimers Disease in September 2021 Business Wire
Aug-04-21 06:30AM	Alzamend Neuro Announces Additional Investment Under Its Investigational New Drug Application for AL001 for Dementia Related to Alzheimers Pursuant to the Securities Purchase Agreement with Digital Power Lending Business Wire
Jul-30-21 06:30AM	Alzamend Neuro Announces Pre-IND Submission for AL002 as a Cell-Based Therapeutic Vaccine That Seeks to Restore the Ability of Patients Immunological System to Combat Alzheimers Business Wire -5.04%
Jul-28-21 03:07PM	Alzamend Neuro Receives FDA "Study May Proceed" Letter for Phase 1 Clinical Study Under Its Investigational New Drug Application for AL001 for Dementia Related to Alzheimers Disease Business Wire +18.10%
Jul-26-21 04:03PM	Why Alzamend Neuro Stock Fell More Than 14% Today Motley Fool -14.31%
Jul-23-21 12:44PM	Here's Why Alzamend Neuro Stock Is Shooting Higher Today Motley Fool
06:30AM	Alzamend Neuro Receives Positive Results for AL002 in a GLP Toxicology Study Using a Transgenic Mouse Model of Alzheimers Disease Business Wire
Jul-12-21 06:00AM	Alzamend Neuro, Inc. to Ring Nasdaq Opening Bell Today Business Wire
Jul-01-21 06:45AM	Ault Global Holdings Announces That Alzamend Neuro Has Submitted an IND Application for AL001 for Dementia Related to Alzheimers Disease Business Wire -12.13%
06:30AM	Alzamend Neuro Submits IND Application for AL001 for Dementia Related to Alzheimers Disease Business Wire
Jun-28-21 03:59PM	Why Alzamend Neuro Stock Popped Today Motley Fool +11.63%
Jun-17-21 04:30PM	Alzamend Neuro Announces Closing of Initial Public Offering and Full Exercise of Underwriters Over-allotment Option for Gross Proceeds of $14.4 Million Business Wire

Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative diseases and psychiatric disorders. Its pipeline includes AL001, an ionic cocrystal technology delivering a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's and other neurodegenerative diseases, and psychiatric disorders; and AL002, a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's. The company was incorporated in 2016 and is headquartered in Atlanta, Georgia.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
AULT MILTON C III	10% Owner	Jun 29	Buy	0.88	10,000	8,830	9,916,667	Jun 30 05:00 PM
AULT MILTON C III	10% Owner	Jun 17	Buy	0.88	10,000	8,841	9,906,667	Jun 21 06:16 PM
AULT MILTON C III	10% Owner	Jun 15	Buy	0.87	10,000	8,740	9,896,667	Jun 16 06:39 PM
AULT MILTON C III	10% Owner	Jun 14	Buy	0.85	10,000	8,474	9,886,667	Jun 15 05:00 PM
AULT MILTON C III	10% Owner	Jun 08	Buy	0.95	8,000	7,576	9,876,667	Jun 09 04:30 PM
AULT MILTON C III	10% Owner	Jun 07	Buy	0.94	2,000	1,881	9,868,667	Jun 08 04:30 PM
AULT MILTON C III	10% Owner	Jun 02	Buy	0.96	8,000	7,679	9,866,667	Jun 03 05:36 PM
AULT MILTON C III	10% Owner	May 27	Buy	0.96	12,000	11,507	9,858,667	May 31 05:00 PM
AULT MILTON C III	10% Owner	May 26	Buy	0.91	10,000	9,120	9,846,667	May 31 05:00 PM
AULT MILTON C III	10% Owner	May 24	Buy	0.89	16,100	14,306	9,836,667	May 26 04:30 PM
AULT MILTON C III	10% Owner	May 17	Buy	0.98	23,900	23,343	9,815,567	May 18 09:20 PM
AULT MILTON C III	10% Owner	May 12	Buy	0.85	25,000	21,318	9,791,667	May 13 05:00 PM
AULT MILTON C III	10% Owner	May 06	Buy	1.00	100,000	99,980	9,766,667	May 13 05:00 PM
AULT MILTON C III	10% Owner	May 05	Buy	1.07	100,000	106,850	325,000	May 06 05:00 PM
Horne William B.	Director	Apr 26	Option Exercise	0.00	250,000	100	500,000	Apr 28 05:01 PM
AULT MILTON C III	10% Owner	Apr 26	Buy	1.50	2,666,667	4,000,000	9,666,667	Apr 28 05:01 PM
AULT MILTON C III	10% Owner	Apr 22	Buy	0.94	75,000	70,335	225,000	Apr 25 04:30 PM
AULT MILTON C III	10% Owner	Apr 11	Buy	1.13	50,000	56,325	150,000	Apr 12 05:00 PM
GUSTAFSON MARK	Director	Mar 31	Sale	1.21	20,000	24,202	60,000	Apr 04 05:00 PM
AULT MILTON C III	10% Owner	Mar 18	Buy	1.10	100,000	110,450	100,000	Mar 21 05:00 PM
Woo Andrew H.	Director	Mar 15	Option Exercise	0.00	50,000	0	100,000	Mar 16 08:21 PM
GUSTAFSON MARK	Director	Mar 15	Option Exercise	0.00	50,000	0	80,000	Mar 15 07:12 PM
McGrath Lynne Fahey	Director	Mar 15	Option Exercise	0.00	50,000	0	100,000	Mar 15 07:09 PM
Oram Jeffrey	Director	Mar 15	Option Exercise	0.00	50,000	0	100,000	Mar 16 04:30 PM
AULT MILTON C III	10% Owner	Feb 24	Buy	1.15	22,500	25,960	7,000,000	Feb 25 04:00 PM
AULT MILTON C III	10% Owner	Feb 01	Option Exercise	0.00	2,250,000	900	2,500,000	Feb 01 05:00 PM
AULT MILTON C III	10% Owner	Jan 27	Buy	1.40	2,500	3,488	6,977,500	Jan 28 06:17 PM
Horne William B.	Director	Jan 24	Option Exercise	0.00	150,000	600	250,000	Jan 25 05:00 PM
AULT MILTON C III	10% Owner	Jan 24	Buy	1.29	5,000	6,450	6,975,000	Jan 25 05:31 PM
AULT MILTON C III	10% Owner	Jan 18	Buy	1.66	7,000	11,619	6,970,000	Jan 19 05:35 PM
AULT MILTON C III	10% Owner	Jan 14	Buy	1.79	3,000	5,368	6,963,000	Jan 18 06:05 AM
AULT MILTON C III	10% Owner	Jan 07	Buy	1.93	3,000	5,775	6,960,000	Jan 11 06:44 PM
AULT MILTON C III	10% Owner	Jan 05	Buy	1.98	2,000	3,959	6,957,000	Jan 06 06:20 PM
AULT MILTON C III	10% Owner	Dec 31	Buy	1.91	8,000	15,290	6,955,000	Jan 03 04:30 PM
AULT MILTON C III	10% Owner	Dec 23	Buy	2.10	1,612	3,377	6,947,000	Dec 27 07:23 PM
AULT MILTON C III	10% Owner	Dec 20	Buy	2.11	25,000	52,665	6,920,388	Dec 20 07:44 PM
AULT MILTON C III	10% Owner	Dec 17	Buy	2.48	13,000	32,304	6,920,388	Dec 20 07:44 PM
GUSTAFSON MARK	Director	Dec 14	Sale	2.85	20,000	57,086	30,000	Dec 16 05:00 PM
AULT MILTON C III	10% Owner	Dec 01	Buy	1.98	17,000	33,725	6,907,388	Dec 02 05:36 PM
AULT MILTON C III	10% Owner	Nov 30	Buy	2.27	5,319	12,058	6,890,388	Dec 02 05:36 PM
AULT MILTON C III	10% Owner	Nov 23	Buy	1.99	4,681	9,315	6,885,069	Nov 23 07:47 PM
AULT MILTON C III	10% Owner	Nov 22	Buy	1.90	15,000	28,498	6,880,388	Nov 23 07:47 PM
AULT MILTON C III	10% Owner	Nov 08	Buy	2.57	145,000	373,114	6,865,388	Nov 10 05:00 PM
AULT MILTON C III	10% Owner	Nov 03	Option Exercise	0.00	100,000	0	250,000	Nov 04 05:00 PM
Woo Andrew H.	Director	Oct 15	Option Exercise	0.00	47,222	0	50,000	Oct 18 05:00 PM
GUSTAFSON MARK	Director	Oct 15	Option Exercise	0.00	47,222	0	50,000	Oct 18 05:00 PM
Oram Jeffrey	Director	Oct 15	Option Exercise	0.00	47,222	0	50,000	Oct 18 05:00 PM
McGrath Lynne Fahey	Director	Oct 15	Option Exercise	0.00	47,222	0	50,000	Oct 18 05:00 PM
AULT MILTON C III	10% Owner	Sep 14	Buy	2.70	5,000	13,492	6,720,388	Sep 16 06:30 PM
Oram Jeffrey	Director	Sep 13	Option Exercise	0.00	2,778	0	2,778	Sep 15 05:00 PM
GUSTAFSON MARK	Director	Sep 13	Option Exercise	0.00	2,778	0	2,778	Sep 15 05:00 PM
McGrath Lynne Fahey	Director	Sep 13	Option Exercise	0.00	2,778	0	2,778	Sep 15 05:01 PM
Woo Andrew H.	Director	Sep 13	Option Exercise	0.00	2,778	0	2,778	Sep 15 05:01 PM
Horne William B.	Director	Sep 08	Option Exercise	0.00	100,000	0	100,000	Sep 10 05:00 PM
AULT MILTON C III	10% Owner	Sep 03	Option Exercise	0.00	150,000	0	150,000	Sep 03 05:07 PM
AULT MILTON C III	10% Owner	Aug 27	Buy	2.90	6,000	17,430	6,715,388	Sep 01 12:01 PM
AULT MILTON C III	10% Owner	Aug 17	Buy	3.29	4,000	13,170	6,709,388	Aug 19 06:32 PM
AULT MILTON C III	10% Owner	Aug 13	Buy	3.56	13,000	46,218	6,705,388	Aug 13 05:24 PM
AULT MILTON C III	10% Owner	Aug 12	Buy	3.87	3,400	13,161	6,692,388	Aug 13 05:24 PM
AULT MILTON C III	10% Owner	Aug 10	Buy	4.01	1,100	4,412	6,688,988	Aug 10 06:17 PM
AULT MILTON C III	10% Owner	Aug 09	Buy	4.05	500	2,027	6,687,888	Aug 10 06:17 PM
AULT MILTON C III	10% Owner	Aug 06	Buy	4.07	4,000	16,275	6,687,388	Aug 10 06:17 PM
AULT MILTON C III	10% Owner	Aug 05	Buy	4.21	1,000	4,210	6,683,388	Aug 06 07:20 PM
AULT MILTON C III	10% Owner	Aug 04	Buy	4.30	500	2,150	6,682,388	Aug 06 07:20 PM
AULT MILTON C III	10% Owner	Aug 03	Buy	4.35	500	2,175	6,681,888	Aug 03 07:45 PM
AULT MILTON C III	10% Owner	Aug 02	Buy	4.56	1,500	6,845	6,681,388	Aug 03 07:45 PM
AULT MILTON C III	10% Owner	Jul 30	Buy	1.51	1,338,333	2,022,843	6,679,888	Aug 03 07:45 PM
AULT MILTON C III	10% Owner	Jul 27	Buy	4.37	4,000	17,467	5,341,555	Jul 27 08:00 PM
AULT MILTON C III	10% Owner	Jul 26	Buy	4.94	3,500	17,298	5,337,555	Jul 27 08:00 PM
AULT MILTON C III	10% Owner	Jul 23	Buy	5.76	5,000	28,788	5,334,055	Jul 27 08:00 PM
AULT MILTON C III	10% Owner	Jul 20	Buy	5.20	3,000	15,604	5,328,555	Jul 22 09:30 PM
AULT MILTON C III	10% Owner	Jul 19	Buy	5.41	4,000	21,650	5,325,555	Jul 19 08:15 PM
AULT MILTON C III	10% Owner	Jul 16	Buy	6.23	600	3,740	5,321,555	Jul 19 08:15 PM
AULT MILTON C III	10% Owner	Jul 15	Buy	6.33	700	4,428	5,321,255	Jul 19 08:15 PM
AULT MILTON C III	10% Owner	Jul 15	Sale	6.92	300	2,076	5,320,955	Jul 19 08:15 PM
AULT MILTON C III	10% Owner	Jul 14	Buy	6.74	5,000	33,687	5,320,055	Jul 14 06:34 PM
AULT MILTON C III	10% Owner	Jul 13	Buy	6.26	900	5,637	5,315,055	Jul 14 06:34 PM
AULT MILTON C III	10% Owner	Jul 12	Buy	6.15	8,100	49,812	5,314,155	Jul 14 06:34 PM
AULT MILTON C III	10% Owner	Jul 08	Buy	6.08	2,000	12,150	5,306,055	Jul 08 07:36 PM
AULT MILTON C III	10% Owner	Jul 07	Buy	6.29	5,000	31,466	5,304,055	Jul 08 07:36 PM
AULT MILTON C III	10% Owner	Jul 06	Buy	7.07	7,000	49,493	5,299,055	Jul 08 07:36 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience